+

WO2003011277A3 - Methods to mobilize progenitor/stem cells - Google Patents

Methods to mobilize progenitor/stem cells Download PDF

Info

Publication number
WO2003011277A3
WO2003011277A3 PCT/US2002/024212 US0224212W WO03011277A3 WO 2003011277 A3 WO2003011277 A3 WO 2003011277A3 US 0224212 W US0224212 W US 0224212W WO 03011277 A3 WO03011277 A3 WO 03011277A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
stem cells
mobilize progenitor
progenitor
mobilize
Prior art date
Application number
PCT/US2002/024212
Other languages
French (fr)
Other versions
WO2003011277A2 (en
Inventor
Gary J Bridger
Michael J Abrams
Geoffrey W Henson
Ronald Trevor Macfarland
Gary B Calandra
Original Assignee
Anormed Inc
Gary J Bridger
Michael J Abrams
Geoffrey W Henson
Ronald Trevor Macfarland
Gary B Calandra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003011277(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2003516507A priority Critical patent/JP5137288B2/en
Priority to BRPI0211570 priority patent/BRPI0211570B8/en
Priority to SI200230976T priority patent/SI1411918T1/en
Priority to EP19179517.8A priority patent/EP3632425A1/en
Priority to DK02750370.5T priority patent/DK1411918T3/en
Priority to CN028149955A priority patent/CN1561208B/en
Priority to AT02750370T priority patent/ATE538785T1/en
Priority to EP02750370A priority patent/EP1411918B1/en
Priority to MXPA04000982A priority patent/MXPA04000982A/en
Priority to ES02750370T priority patent/ES2380009T3/en
Priority to PL02364673A priority patent/PL364673A1/en
Priority to EP10184509.7A priority patent/EP2371361B1/en
Priority to HU0402360A priority patent/HUP0402360A2/en
Priority to IL15931202A priority patent/IL159312A0/en
Priority to KR10-2004-7001333A priority patent/KR20040020075A/en
Priority to CA2455559A priority patent/CA2455559C/en
Priority to AU2002318927A priority patent/AU2002318927B2/en
Priority to NZ530169A priority patent/NZ530169A/en
Application filed by Anormed Inc, Gary J Bridger, Michael J Abrams, Geoffrey W Henson, Ronald Trevor Macfarland, Gary B Calandra filed Critical Anormed Inc
Publication of WO2003011277A2 publication Critical patent/WO2003011277A2/en
Publication of WO2003011277A3 publication Critical patent/WO2003011277A3/en
Priority to IL159312A priority patent/IL159312A/en
Priority to ZA2004/00658A priority patent/ZA200400658B/en
Priority to NO20040407A priority patent/NO336989B1/en
Priority to HK04104446.8A priority patent/HK1063005A1/en
Priority to CY2012017C priority patent/CY2012017I2/en
Priority to LU92033C priority patent/LU92033I2/en
Priority to NL300537C priority patent/NL300537I2/nl
Priority to DE201212000044 priority patent/DE122012000044I1/en
Priority to FR12C0042C priority patent/FR12C0042I1/en
Priority to NO20150674A priority patent/NO344632B1/en
Priority to NO2016011C priority patent/NO2016011I1/en
Priority to CY20191100889T priority patent/CY1122199T1/en
Priority to FR19C1058C priority patent/FR19C1058I2/en
Priority to CY2019038C priority patent/CY2019038I1/en
Priority to BE2019C544C priority patent/BE2019C544I2/fr
Priority to LTPA2019018C priority patent/LTC2371361I2/en
Priority to LU00139C priority patent/LUC00139I2/fr
Priority to NL301031C priority patent/NL301031I2/en
Priority to NO2020003C priority patent/NO2020003I1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is directed to methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4.
PCT/US2002/024212 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells WO2003011277A2 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
HU0402360A HUP0402360A2 (en) 2001-07-31 2002-07-30 Use of polyamines for the production of pharmaceutical preparations suitable for increasing the number of progenitor cells and/or stem cells
PL02364673A PL364673A1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
SI200230976T SI1411918T1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
EP19179517.8A EP3632425A1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
DK02750370.5T DK1411918T3 (en) 2001-07-31 2002-07-30 Methods for mobilizing progenitor / stem cells
CN028149955A CN1561208B (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
AT02750370T ATE538785T1 (en) 2001-07-31 2002-07-30 METHOD FOR MOBILIZING PROCURSIONS/STEM CELLS
EP02750370A EP1411918B1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
MXPA04000982A MXPA04000982A (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells.
JP2003516507A JP5137288B2 (en) 2001-07-31 2002-07-30 How to mobilize progenitor / stem cells
EP10184509.7A EP2371361B1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
BRPI0211570 BRPI0211570B8 (en) 2001-07-31 2002-07-30 use of 1'-[1,4-phenylene-bis(methylene)-bis-1,4,8,11-tetrazacyclotetradecane or a pharmaceutically acceptable salt thereof in the preparation of a composition for collecting progenitor and/or stem cells
ES02750370T ES2380009T3 (en) 2001-07-31 2002-07-30 Methods to mobilize stem / progenitor cells
IL15931202A IL159312A0 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
KR10-2004-7001333A KR20040020075A (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
CA2455559A CA2455559C (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
AU2002318927A AU2002318927B2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
NZ530169A NZ530169A (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
IL159312A IL159312A (en) 2001-07-31 2003-12-11 Compound represented by the formula z-linker-z' (formula 1) for use in a method to obtain progenitor/stem cells
ZA2004/00658A ZA200400658B (en) 2001-07-31 2004-01-27 Methods to mobilize progenitor stem cells
NO20040407A NO336989B1 (en) 2001-07-31 2004-01-29 Compound for use in a method of treating a hematopoietic deficiency from chemotherapy or radiation therapy in an individual
HK04104446.8A HK1063005A1 (en) 2001-07-31 2004-06-18 Methods to mobilize progenitor/stem cells
CY2012017C CY2012017I2 (en) 2001-07-31 2012-06-27 METHODS FOR MOBILIZING PROGENITOR/STEM CELLS
LU92033C LU92033I2 (en) 2001-07-31 2012-06-27 Plerixafor and its pharmaceutically acceptable derivatives (MOZOBIL®)
NL300537C NL300537I2 (en) 2001-07-31 2012-06-28
DE201212000044 DE122012000044I1 (en) 2001-07-31 2012-06-28 Method for mobilizing precursors / stemm cells.
FR12C0042C FR12C0042I1 (en) 2001-07-31 2012-06-28 METHODS OF MOBILIZING STEM/EMBRYONIC CELLS
NO20150674A NO344632B1 (en) 2001-07-31 2015-05-27 Compound for use in method of mobilizing and harvesting progenitor / stem cells
NO2016011C NO2016011I1 (en) 2001-07-31 2016-06-10 plerixafor 1,1 '- [1,4-phenylenebis (methylene)] bis [1,4,8,11-tetraazacyclotetradecane]
CY20191100889T CY1122199T1 (en) 2001-07-31 2019-08-20 METHODS FOR MOBILIZATION OF PROGNETER / STEM CELL CELLS
FR19C1058C FR19C1058I2 (en) 2001-07-31 2019-10-10 STEM/EMBRYONIC CELL MOBILIZATION METHODS
CY2019038C CY2019038I1 (en) 2001-07-31 2019-10-14 METHODS FOR MOBILIZING PROGENITOR/STEM CELLS
BE2019C544C BE2019C544I2 (en) 2001-07-31 2019-10-23
LTPA2019018C LTC2371361I2 (en) 2001-07-31 2019-11-19 PRIMARY / STEM CELL ACTIVATION METHODS
LU00139C LUC00139I2 (en) 2001-07-31 2019-11-26
NL301031C NL301031I2 (en) 2001-07-31 2020-01-22 Plerixafor, optionally in the form of a pharmaceutically acceptable salt or metal complex thereof
NO2020003C NO2020003I1 (en) 2001-07-31 2020-03-05 plerixafor (1,1 '- [1,4-phenylene-bis- (methylene)] - bis1,2,8,11-tetraazacyclotetradecane) optionally in the form of a pharmaceutically acceptable salt or metal complex thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US60/309,196 2001-07-31
US38215502P 2002-05-20 2002-05-20
US60/382,155 2002-05-20

Publications (2)

Publication Number Publication Date
WO2003011277A2 WO2003011277A2 (en) 2003-02-13
WO2003011277A3 true WO2003011277A3 (en) 2003-05-22

Family

ID=26976666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024212 WO2003011277A2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells

Country Status (29)

Country Link
US (9) US6987102B2 (en)
EP (3) EP3632425A1 (en)
JP (2) JP5137288B2 (en)
KR (2) KR20040020075A (en)
CN (2) CN1561208B (en)
AT (1) ATE538785T1 (en)
AU (1) AU2002318927B2 (en)
BE (1) BE2019C544I2 (en)
BR (1) BRPI0211570B8 (en)
CA (1) CA2455559C (en)
CY (4) CY1112633T1 (en)
DK (2) DK1411918T3 (en)
ES (2) ES2742730T3 (en)
FR (2) FR12C0042I1 (en)
HK (1) HK1063005A1 (en)
HU (1) HUP0402360A2 (en)
IL (2) IL159312A0 (en)
LT (2) LT2371361T (en)
LU (2) LU92033I2 (en)
MX (1) MXPA04000982A (en)
NL (2) NL300537I2 (en)
NO (4) NO336989B1 (en)
NZ (1) NZ530169A (en)
PL (1) PL364673A1 (en)
PT (2) PT2371361T (en)
RU (1) RU2309741C2 (en)
SI (2) SI2371361T1 (en)
WO (1) WO2003011277A2 (en)
ZA (1) ZA200400658B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285424B2 (en) 2020-03-10 2025-04-29 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2742730T3 (en) * 2001-07-31 2020-02-17 Genzyme Corp Progenitor cell / mother cell mobilization methods
CN1596255A (en) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
JP4667241B2 (en) * 2003-06-27 2011-04-06 旭化成株式会社 Cell differentiation inhibitor, cell culture method using the same, culture solution and cultured cell line
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1656451A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
BRPI0514343A (en) * 2004-08-13 2008-06-10 Anormed Inc chemokine combinations to mobilize progenitor / stem cells
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
EP1814587A2 (en) 2004-11-05 2007-08-08 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
KR101604799B1 (en) 2005-06-13 2016-03-28 클리브랜드 바이오랩스, 아이엔씨. Methods of protecting against apoptosis using lipopeptides
WO2007022523A2 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
EP2267030A1 (en) * 2005-08-25 2010-12-29 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
WO2007106063A2 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
JP2010507567A (en) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション Combination therapy
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2011053700A1 (en) * 2009-10-28 2011-05-05 Henry Ford Health System Methods to mitigate injury from radiation exposure
CN101716167B (en) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 Use of saturated amine compound in preparation of medicaments for mobilizing peripheral blood hematopoietic stem cells
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2709991B1 (en) 2011-05-16 2020-09-02 Genzyme Corporation Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
US20160030522A1 (en) * 2013-03-15 2016-02-04 Leonard B. Miller Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
JP2018531229A (en) 2015-09-18 2018-10-25 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル Local delivery of anti-fugetactic agents for the treatment of cancer
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
PT3393468T (en) 2015-12-22 2023-01-19 X4 Pharmaceuticals Inc METHODS TO TREAT IMMUNODEFICIENCIES
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHODS OF TREATING CANCER
EP3471716A1 (en) * 2016-06-16 2019-04-24 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
JP7084624B2 (en) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド CXCR4 inhibitor and its use
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
US11325951B2 (en) 2016-09-09 2022-05-10 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of cancer
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
WO2019113375A2 (en) * 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3086337A1 (en) * 2017-12-19 2019-06-27 Gpcr Therapeutics, Inc. Gpcr heteromer inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en) 2019-10-08 2024-08-13 The Regents Of The University Of California Methods and compositions for hematopoietic stem cell mobilization
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
CN118660955A (en) 2021-10-01 2024-09-17 詹森药业有限公司 Methods for increasing progenitor cell production
CN118987175A (en) * 2024-08-13 2024-11-22 广东壹加再生医学研究院有限公司 Application of plexafet and granulocyte colony stimulating factor in preparation of medicine for treating cerebral infarction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US5583131A (en) * 1991-12-16 1996-12-10 Johnson Matthey Public Limited Company Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
US5698546A (en) * 1994-01-11 1997-12-16 Johnson Matthey Public Limted Company Cyclic polyamines

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (en) 1987-08-24 1989-03-16 Schering Ag MULTI-CORE SUBSTITUTED COMPLEX ILLUMINATORS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
FR2644453A1 (en) * 1989-03-20 1990-09-21 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF MONOFUNCTIONALIZED CYCLIC TETRAMINES
CA2069886A1 (en) 1989-10-23 1991-04-24 David Love Multi-site metal chelating agents
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
FR2672051B1 (en) * 1991-01-24 1993-05-21 Guerbet Sa NOVEL NITROGEN MACROCYCLIC LIGANDS, PREPARATION METHOD, POLYMETALLIC COMPLEXES, DIAGNOSTIC AND THERAPEUTIC COMPOSITION.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
JPH08127539A (en) * 1994-10-31 1996-05-21 Ajinomoto Co Inc Human il-11-containing peripheral blood stem cell proliferator
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (en) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd Medicine for increasing number of hematopoietic stem cells in peripheral blood
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
JP4786793B2 (en) * 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス，インコーポレイティド Therapeutic and diagnostic applications based on the role of CXCR-4 gene in tumorigenesis
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
EP1117762A4 (en) * 1998-09-29 2004-02-25 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
EP1133291B1 (en) * 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
MXPA01009674A (en) 1999-03-24 2003-07-21 Anormed Inc Chemokine recpetor binding heterocyclic compounds.
AU4692400A (en) * 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
CA2389545C (en) * 1999-12-17 2010-08-31 Anormed Inc. Chemokine receptor binding heterocyclic compounds
ATE265219T1 (en) 2000-05-09 2004-05-15 Univ British Columbia USE OF CXCR4 ANTAGONISTS TO TREAT CANCER AND AUTOIMMUNE DISEASES
JP5414958B2 (en) * 2000-06-05 2014-02-12 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Identification of human bone marrow-derived endothelial progenitor cells and use of human bone marrow-derived endothelial progenitor cells to improve the function of cardiomyocytes after ischemic injury
NZ524420A (en) 2000-09-15 2005-04-29 Anormed Inc Chemokine receptor binding heterocyclic compounds
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
KR20030029997A (en) 2000-09-15 2003-04-16 아노르메드 인코포레이티드 Chemokine receptor binding heterocyclic compounds
PL359292A1 (en) 2000-09-29 2004-08-23 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
ATE354344T1 (en) 2001-01-23 2007-03-15 P & G Clairol Inc PRIMARY INTERMEDIATE PRODUCTS FOR OXIDATIVE HAIR COLORING
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2742730T3 (en) 2001-07-31 2020-02-17 Genzyme Corp Progenitor cell / mother cell mobilization methods
CN1596255A (en) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (en) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Domestic refrigerating appliance with a dispenser unit with two closure elements on a delivery channel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US5583131A (en) * 1991-12-16 1996-12-10 Johnson Matthey Public Limited Company Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
US5698546A (en) * 1994-01-11 1997-12-16 Johnson Matthey Public Limted Company Cyclic polyamines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285424B2 (en) 2020-03-10 2025-04-29 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Also Published As

Publication number Publication date
FR12C0042I1 (en) 2012-08-10
WO2003011277A2 (en) 2003-02-13
CA2455559A1 (en) 2003-02-13
US7897590B2 (en) 2011-03-01
US20190216773A1 (en) 2019-07-18
CY2012017I1 (en) 2015-08-05
CY2019038I2 (en) 2020-05-29
US20060193826A1 (en) 2006-08-31
LU92033I2 (en) 2012-08-27
AU2002318927B2 (en) 2007-01-04
HK1063005A1 (en) 2004-12-10
ZA200400658B (en) 2005-07-27
NO2020003I1 (en) 2020-03-05
EP1411918B1 (en) 2011-12-28
HUP0402360A2 (en) 2005-02-28
LUC00139I2 (en) 2021-02-10
LT2371361T (en) 2019-09-10
ES2380009T3 (en) 2012-05-07
EP2371361B1 (en) 2019-08-07
PT1411918E (en) 2012-03-06
CY1122199T1 (en) 2020-05-29
DK2371361T3 (en) 2019-08-19
BR0211570A (en) 2004-07-13
CN1561208B (en) 2010-11-10
NO20040407L (en) 2004-03-19
KR20090130152A (en) 2009-12-17
EP1411918A2 (en) 2004-04-28
LU92033I9 (en) 2019-01-03
CN102302493A (en) 2012-01-04
EP3632425A1 (en) 2020-04-08
LUC00139I1 (en) 2019-11-27
NZ530169A (en) 2007-04-27
RU2004105961A (en) 2005-03-20
BRPI0211570B8 (en) 2021-05-25
KR20040020075A (en) 2004-03-06
CA2455559C (en) 2012-01-10
IL159312A (en) 2015-05-31
CY2019038I1 (en) 2020-05-29
SI2371361T1 (en) 2019-10-30
US20110129448A1 (en) 2011-06-02
PT2371361T (en) 2019-09-10
JP2004538303A (en) 2004-12-24
KR100996378B1 (en) 2010-11-25
US7935692B2 (en) 2011-05-03
US20080063624A1 (en) 2008-03-13
NO20150674A1 (en) 2015-05-27
JP2008195730A (en) 2008-08-28
NL300537I2 (en) 2017-02-02
NL301031I2 (en) 2020-07-20
NO336989B1 (en) 2015-12-14
ATE538785T1 (en) 2012-01-15
LTPA2019018I1 (en) 2019-12-10
FR19C1058I1 (en) 2019-11-22
NO344632B1 (en) 2020-02-17
ES2742730T3 (en) 2020-02-17
JP5137288B2 (en) 2013-02-06
US20150246019A1 (en) 2015-09-03
SI1411918T1 (en) 2012-04-30
PL364673A1 (en) 2004-12-13
US20060223180A1 (en) 2006-10-05
FR19C1058I2 (en) 2020-10-23
RU2309741C2 (en) 2007-11-10
US20030130250A1 (en) 2003-07-10
CY1112633T1 (en) 2015-08-05
US20170049747A1 (en) 2017-02-23
EP2371361A1 (en) 2011-10-05
BE2019C544I2 (en) 2021-07-19
NO2016011I1 (en) 2016-06-10
EP1411918A4 (en) 2007-11-14
US6987102B2 (en) 2006-01-17
BRPI0211570B1 (en) 2020-01-28
MXPA04000982A (en) 2004-04-20
US20130273009A1 (en) 2013-10-17
CN102302493B (en) 2015-08-12
CN1561208A (en) 2005-01-05
LTC2371361I2 (en) 2021-09-27
DK1411918T3 (en) 2012-04-23
NL301031I1 (en) 2020-02-05
CY2012017I2 (en) 2015-08-05
IL159312A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
WO2003011277A3 (en) Methods to mobilize progenitor/stem cells
WO2006020891A3 (en) Chemokine combinations to mobilize progenitor/stem cells
WO2001085196A3 (en) Cxcr4 antagonist treatment of hematopoietic cells
AU7924501A (en) Progenitor cells and methods and uses related thereto
AU2002359340A1 (en) Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
HK1050427A1 (en) Bipolar plates and end plates for fuel cells and methods for making the same
WO2004096798A3 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2001011011A3 (en) Multipotent adult stem cells and methods for isolation
EP1924649A4 (en) Electrolyte comprising eutectic mixture and electrochemical device using the same
NZ612132A (en) Immunomodulation using placental stem cells
WO2006063072A3 (en) Immunomodulatory compositions, combinations and methods
AU2003298016A1 (en) Homologous recombination in multipotent adult progenitor cells
IL173369A (en) Combined pharmaceutical preparation containing g - csf and p1gf effective in stimulating mobilization of peripheral blood progenitor cells
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
HK1067137A1 (en) Solid electrolyte and electrochemical system using the solid electrolyte
IN266744B (en)
EP1771903A4 (en) Ruthenium-rhodium alloy electrode catalyst and fuel cell comprising the same
AU2003221173A1 (en) Placenta-origin mesenchymal cells and medicinal use thereof
WO2004001009A3 (en) Apo-2 ligand/trail variants and uses thereof
WO2005065456A3 (en) Active substance combinations having insecticidal properties
HUP0200484A2 (en) Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
IL174827A0 (en) Antibodies to nik preparation and use
AU2003266282A8 (en) Compositions comprising muscle progenitor cells and uses thereof
WO2007005605A3 (en) Phosphospecific chemokine receptor antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1600/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 159312

Country of ref document: IL

Ref document number: 2002318927

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 530169

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003516507

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500081

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2002750370

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/00658

Country of ref document: ZA

Ref document number: 200400658

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020047001333

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000982

Country of ref document: MX

Ref document number: 20028149955

Country of ref document: CN

Ref document number: 2455559

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002750370

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1020097024731

Country of ref document: KR

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载